DRUG
Tesamorelin (Egrifta)
We will observe the effects of Tesamorelin on patients with HIV and lipodystrophy.
Status
Withdrawn
Phase
Not applicable
Enrollment
0
Locations
1
Results
Not posted
Publications
0
Study summary
Sleep-disordered breathing is characterized primarily by partial or total upper airway obstruction during sleep. The most common form of sleep-disordered breathing is obstructive sleep apnea (OSA) due to recurrent collapse of the upper airway with the onset of sleep state. The major risk factors associated with the development of sleep apnea are obesity and male sex. The investigators have also found a high prevalence of OSA in HIV infected men and women, particularly among those with central lipohypertrophy, which is a common finding in HIV-infected persons receiving antiretroviral therapy. Currently, our overall hypothesis is that visceral adiposity, as seen in HIV-infected persons with central lipohypertrophy, alters both mechanical properties and compensatory neuromuscular responses leading to upper airway obstruction. Based on our most recent findings in the non-HIV population, the investigators demonstrate that obesity is associated with elevations in the upper airway load (passive Pcrit) that are counterbalanced by compensatory upper airway neural responses. Moreover, the investigators have found that female sex, peripheral adiposity, and younger age are associated with increased compensatory neuromuscular responses, while male sex, central adiposity, and older age are associated with blunted compensatory responses. The loss of the compensatory neuromuscular responses leads to obstructive sleep apnea. Among HIV-infected patients with central lipohypertrophy, tesamorelin (Egrifta), a growth hormone releasing hormone (GHRH) analogue, is approved for the reduction of visceral adipose tissue. The investigators hypothesize that tesamorelin therapy will reverse both the mechanical and neurocompensatory alterations associated with increased central obesity. In this project the investigators will determine whether tesamorelin affects sleep apnea severity and compensatory neuromuscular responses of the upper airway on sleep and breathing in men and women with HIV infection. The proposed studies are designed to elucidate the pathophysiologic basis for the development of obstructive sleep apnea in this population. The studies also provide insights into the neurohumoral regulation of upper airway function, and potentially new approaches to the treatment for sleep-disordered breathing.
Interventions
DRUG
We will observe the effects of Tesamorelin on patients with HIV and lipodystrophy.
Timeline
First posted
Feb 11, 2013
Study start
May 2012
Primary completion
Jan 2020
Study completion
Not reported
Results posted
Not reported
Registry updated
Mar 3, 2017
Outcomes
Changes in Sleep Apnea Severity
Time frame · Subjects will be evaluated prior to initiating tesamorelin therapy (baseline)
Sleep apnea severity (AHI), change in sleep apnea severity (∆ AHI), and compensatory neuromuscular responses (AT/DBT, ∆ AT/DBT) will be the primary outcome variables.
Changes in Sleep Apnea Severity
Time frame · Subjects will be evaluated at three months
Sleep apnea severity (AHI), change in sleep apnea severity (∆ AHI), and compensatory neuromuscular responses (AT/DBT, ∆ AT/DBT) will be the primary outcome variables.
Changes in Sleep Apnea Severity
Time frame · Subjects will be evaluated at six months
Sleep apnea severity (AHI), change in sleep apnea severity (∆ AHI), and compensatory neuromuscular responses (AT/DBT, ∆ AT/DBT) will be the primary outcome variables.
Changes in Sleep Apnea Severity
Time frame · Subjects will be evaluated at one year
Sleep apnea severity (AHI), change in sleep apnea severity (∆ AHI), and compensatory neuromuscular responses (AT/DBT, ∆ AT/DBT) will be the primary outcome variables.
Changes in Body Composition
Time frame · baseline
Secondary outcomes will include the percent change in anthropometric and body composition parameters as reflected by Dual-Energy Xray Absorbtiometry measurements.
Changes in Body Composition
Time frame · 12 months
Secondary outcomes will include the percent change in anthropometric and body composition parameters as reflected by Dual-Energy Xray Absorbtiometry measurements.
Eligibility
Inclusion Criteria: 1. Consenting adult with documented HIV-infection, ages 18 - 75 years old 2. Central lipohypertrophy as determined by a clinician 3. Not currently on Egrifta (tesamorelin) therapy. Exclusion Criteria: 1. Unstable cardiovascular disease (decompensated CHF, myocardial infarction in past 3 months, revascularization procedure in past 3 months, and unstable arrhythmias); 2. Uncontrolled hypertension (BP \> 190/110); 3. Presence of cor pulmonale 4. History of end stage renal disease (on dialysis); 5. History of end stage liver disease ( e.g. jaundice, ascites, history of recurrent gastrointestinal bleeding, transjugular intrahepatic portosystemic shunt (TIPS) ; 6. Bleeding disorders or coumadin use; 7. Tracheostomy 8. Active malignancy 9. Pregnancy and/or nursing mother -
Study locations
United States. Showing up to 24 locations stored in the fast local snapshot.
Johns Hopkins Sleep Disorders Center
Baltimore, Maryland, United States
Publications
No PMID-linked publications were present in this registry snapshot.
Related trials
Columbia University · HIV Lipodystrophy Syndrome · Growth Hormone Deficiency
Phase 4
Terminated
6
2026-05
Massachusetts General Hospital · HIV-1-infection · Frailty
Phase 2
Recruiting
100
2026-05
Hudson Biotech · Metabolic Associated Steatotic Liver Disease · Nonalcoholic Steatohepatitis
Phase 2
Recruiting
120
2026-03
University of California, San Diego · Mild Cognitive Impairment
Phase 2
Completed
73
2026-03
Massachusetts General Hospital · Non-Alcoholic Fatty Liver Disease · Obesity
Phase 2
Completed
51
2025-11
Johns Hopkins University · Peripheral Nerve Injuries
Phase 2
Recruiting
36
2025-11
Theratechnologies · Lipodystrophy · HIV Infections
Phase 3
Completed
263
2022-09
Massachusetts General Hospital · Human Immunodeficiency Virus · Lipodystrophy
Not applicable
Completed
23
2022-07
Related PeptideStat pages
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.